Drug Topics
MARCH 11, 2024
A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.
STAT
MARCH 11, 2024
UnitedHealth Group quietly acquired dozens of outpatient facilities in 2023, with a particular focus on surgery centers, according to a STAT review of company financial filings. Those acquisitions — nearly all of which the company never announced — build on the network of some 90,000 physicians UnitedHealth Group has amassed in recent years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MARCH 11, 2024
Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.
STAT
MARCH 11, 2024
Despite being the largest minority in the nation , disabled people like us have been structurally and institutionally obstructed from entering research-dominated fields. When they do manage to break through, they are seldom given the support and accommodations needed to sustain employment and thrive in their professional lives. As we have experienced, including people with disabilities in academic leadership and decision-making positions can lead to innovation, creative problem-solving, and insi
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
MARCH 11, 2024
The IVIG therapies were previously approved for 4-week room temperature storage conditions of 25º Celsius during the first 24 months of shelf life.
Fierce Pharma
MARCH 11, 2024
The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended. The FDA has approved Madrigal's resmetirom under the brand name Rezdiffra as the first drug for the fatty liver disease.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
MARCH 11, 2024
If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.
Fierce Healthcare
MARCH 11, 2024
ORLANDO — Generative AI continues to be a big buzzword in 2024 as tech companies see the potential to use the technology to alleviate administrative drudgery for healthcare workers. | Google Cloud is using its tech muscle to build out generative AI capabilities for healthcare and life sciences companies to help offload administrative burden and support assistive technology for clinicians.
STAT
MARCH 11, 2024
Hundreds of messages from an internal chat board for an international group of transgender health professionals were leaked in a think tank report last week and framed as revealing serious health risks associated with gender-affirming care, including cancer. But experts say this correlation is false and oversimplifies the complex role of hormones in the body.
Fierce Healthcare
MARCH 11, 2024
ORLANDO, Florida—HIMSS24 just kicked off today, and there's already a stream of AI innovation news. | ORLANDO, Florida—Symplr is working with Amazon Web Services to develop AI assistants to help automate complex workflows and mundane tasks for healthcare workers and also power chatbots to help patients find and schedule the right care.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
MARCH 11, 2024
LONDON — Regulators, clinicians, and health care algorithm developers need to take additional steps to ensure that medical devices work equally well for all patients, avoiding blind spots that can lead to worse care for patients from underrepresented racial and ethnic groups, according to a U.K.-commissioned review released on Monday. The report, which also warned about the products’ biases potentially hurting women and people from lower socioeconomic groups, called on the governme
Fierce Healthcare
MARCH 11, 2024
President Biden unveiled a proposed $7.3 trillion budget for fiscal year 2025 on Monday, which continued upon and expanded key health items from previous years. | Drug price negotiations and Medicare solvency were just two areas HHS officials hit upon while unveiling President Biden's 2025 fiscal year proposed budget.
Pharmacy Times
MARCH 11, 2024
This initiative aims to raise worldwide awareness of the disease while trying to strengthen the connection between members of the multiple myeloma community.
Fierce Healthcare
MARCH 11, 2024
Sixteen health systems, Microsoft and other healthcare technology organizations are the latest to band together and hammer out best practices and standards for AI in care. | The latest provider-tech AI collaboration will build on the groundwork of members' existing AI partnership, the Coalition for Health AI.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
MARCH 11, 2024
On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.
Fierce Healthcare
MARCH 11, 2024
The federal government is pressing UnitedHealth Group and other payers to provide financial relief to providers as they continue to feel the financial disruption caused by the Change Healthcare cyb | The federal government is pressing UnitedHealth Group and other payers to provide financial relief to providers as they continue to feel the financial disruption caused by the Change Healthcare cyberattack.
STAT
MARCH 11, 2024
Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.
Fierce Healthcare
MARCH 11, 2024
Onboarding new graduates into healthcare has become more difficult following pandemic disruptions and will require greater attention and investment from the industry in order to stem preventable pa | Clinicians-in-training had fewer opportunities for hands-on learning and practice due to the pandemic, which has also driven away many of the experienced healthcare workers who would share their knowledge on the job, the healthcare quality and safety group wrote in a new report.
pharmaphorum
MARCH 11, 2024
Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated approval in jeopardy.
Fierce Pharma
MARCH 11, 2024
Bluebird Bio has secured its first Medicaid outcomes-based agreement for its sickle cell disease gene therapy Lyfgenia, signing on with Michigan.
Pharmaceutical Technology
MARCH 11, 2024
Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.
Fierce Pharma
MARCH 11, 2024
After a pair of approvals in recent years and as its sales continue to climb, Incyte's topical JAK inhibitor Opzelura is adding to its clinical case with trial results that demonstrate its benefits | The company presented positive data from a phase 2 study in mild-to-moderate hidradenitis suppurativa at the American Academy of Dermatology's annual meeting on Sunday.
pharmaphorum
MARCH 11, 2024
Enhancing clinical trial outcomes through algorithmic prespecification in subgroup analysis can provide valuable insights for the FDA and medical community. Learn more about this practice and its importance in clinical research.
Fierce Pharma
MARCH 11, 2024
Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Co | Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.
pharmaphorum
MARCH 11, 2024
Stay updated with the latest pharma and biotech hires from February 2024 at companies like AbbVie, Astellas, EnteroBiotix, and Resalis Therapeutics in Changing Faces.
Pharmacy Times
MARCH 11, 2024
Contract pharmacies should work to stay in a perpetual state of audit readiness
pharmaphorum
MARCH 11, 2024
Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese
STAT
MARCH 11, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about a new online marketplace to trade animal parts for research, an initiative to ensure ethics in AI-driven protein synthesis, and more.
The Checkup by Singlecare
MARCH 11, 2024
Coenzyme Q10 (CoQ10) is a popular over-the-counter (OTC) dietary supplement, thanks to its many health benefits. Also known as ubiquinone or ubiquinol , CoQ10 is a fat-soluble antioxidant found in nearly all of the cells in your body—mainly, it’s found in the cell membranes (the part of the cell that separates from its outside environment)—in the highest concentrations in your liver, kidneys, pancreas, and heart.
pharmaphorum
MARCH 11, 2024
Learn about the warning signs for potential secondary cancer cases related to CAR-T therapies. Understand the risks associated with cytokine release syndrome and other side effects of CAR-T treatment.
The Checkup by Singlecare
MARCH 11, 2024
You’re coughing, wheezing, and feeling short of breath, but are your symptoms caused by asthma or bronchitis? It can be hard to tell the difference. Both conditions are relatively common. Asthma affects more than 27 million Americans and is the leading cause of chronic disease in children. Acute bronchitis is most often caused by colds and other viruses and sends about 5% of adults to their healthcare provider each year, most often during winter months.
STAT
MARCH 11, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings, calls, and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup of stimulation.
Fierce Pharma
MARCH 11, 2024
Ever since its first FDA rejection five years ago, Lexicon Pharmaceuticals hasn’t given up hope on its Type 1 diabetes prospect sotagliflozin. | The company hopes its long and bumpy five-year journey will soon see an end with an FDA approval. Lexicon looks to resubmit the drug by the middle of the year.
pharmaphorum
MARCH 11, 2024
Stay updated on the latest developments in clinical trials with highlights from Medigene, Artax, and KalVista from 12th to 16th February 2024.
Expert insights. Personalized for you.
212 
Let's personalize your content